Head-to-head evidence
Emraclidine vs NBI-1117568
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Muscarinic M4 receptor · full Schizophrenia pipeline
Emraclidine
Developed by Pfizer and partners
NCT05227703 · Phase 2 · completed
Participants were randomly assigned to emraclidine 15 mg, emraclidine 30 mg, or matching placebo and were double-blinded, with 130–131 participants per group. The primary clinical endpoint was not met: the Week 6 PANSS comparison was nonsignificant for both 15 mg versus placebo (p=0.2925) and 30 mg versus placebo (p=0.3914).
Next expected readout: February 2028 · NCT07145918 (registry estimate)
NBI-1117568
Developed by Neurocrine Biosciences under a licence from Nxera Pharma
NCT05545111 · Phase 2 · completed
The study randomly assigned 210 participants to four NBI-1117568 dose groups or placebo and used quadruple masking of participants, care providers, investigators, and outcome assessors. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: October 2027 · NCT06963034 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Emraclidine's landscape · NBI-1117568's landscape